869185-85-3
| 中文名称 | 869185-85-3 |
|---|---|
| 中文同义词 | 化合物 T21675;SB 203580盐酸盐 |
| 英文名称 | SB 203580 (hydrochloride) |
| 英文同义词 | RWJ 64809 hydrochloride;RWJ 64809 HYDROCHLORIDE;SB203580 HYDROCHLORIDE;SB-203580 HYDROCHLORIDE;SB 203580, Hydrochloride - CAS 869185-85-3 - Calbiochem;Adezmapimod (hydrochloride);Adezmapimod (SB-203580) hydrochloride |
| CAS号 | 869185-85-3 |
| 分子式 | C21H17ClFN3OS |
| 分子量 | 413.9 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 869185-85-3.mol |
| 结构式 |  |
869185-85-3 性质
| 储存条件 | -20C |
|---|---|
| 溶解度 | 不溶于乙醇；不溶于水； DMSO 中≥20.7 mg/mL |
| 形态 | 亮黄色固体 |
| 颜色 | 浅黄至黄色 |
| 水溶解性 | Soluble to 25 mM in water |
| 稳定性 | 吸湿性 |
|
p38 50 nM (IC 50 ) |
p38β2 500 nM (IC 50 ) |
SB 203580 (preincubated with 0-30 μM for 1 h and cultured for 24 h in the presence of 20 ng/mL IL-2) prevents the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC
50
of 3-5 μM.
SB203580 blocks PKB phosphorylation (IC
50
3-5 μM). SB203580 inhibitsthe phosphorylation of Ser473 in a dose-dependent manner in both CT6 and activated human T cells and IL-2-responsive BA/F3 F7 B cells.
Cell Proliferation Assay
| Cell Line: | CT6, BA/F3 cell line F7, and PBMC/T cells |
| Concentration: | 0-30 μM |
| Incubation Time: | Preincubated with 0-30 μM SB203580 for 1 h and cultured for 24 h in the presence of 20 ng/mL IL-2 |
| Result: | Prevented the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC 50 of 3-5 μM. |
Western Blot Analysis
| Cell Line: | CT6 cells, activated human T cells, and BA/F3 F7 cells |
| Concentration: | 0-30 μM |
| Incubation Time: | Preincubated with 0-30 μM SB203580 for 1 h before stimulating with 20 ng/mL IL-2 for 5 min |
| Result: | Inhibited the phosphorylation of PKB at Ser473 in a dose-dependent manner. |
SB203580 (5 mg/kg/day; intra peritoneal injected daily for 16 consecutive days, in female atymic Nu/Nu mice) treatment, p38WT tumors show a significantly smaller tumor burden when compared with p38TM tumors that were treated in parallel.
| Animal Model: | Six-week-old female atymic Nu/Nu mice CAL27 p38WT and p38TM tumors |
| Dosage: | 5 mg/kg/day |
| Administration: | Intra peritoneal injected daily for 16 consecutive days |
| Result: | After 2 weeks treatment, CAL27 p38WT tumors were significantly smaller; CAL27 p38TM tumors were not affected by the p38 inhibitor (n=10). |
安全信息
| 海关编码 | 2933399990 |
|---|
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-10256A | Adezmapimod hydrochloride | 5 mg | 330元 | |
| 2024/04/30 | HY-10256A | 869185-85-3 Adezmapimod hydrochloride | 869185-85-3 | 10mM * 1mLin DMSO | 363元 |